Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin
The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in patients at high risk with concomitant metabolic comorbidities. Evidences for novel modern approaches regarding primary prevention of cardiovascular events among dyslipidemic patients are considered. The...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine"
2015-06-01
|
Series: | Medičnì Perspektivi |
Subjects: | |
Online Access: | http://medpers.dsma.dp.ua/issues/2015/N2/54-62.pdf |
id |
doaj-3d0f5f92c9f74eab88843644128facef |
---|---|
record_format |
Article |
spelling |
doaj-3d0f5f92c9f74eab88843644128facef2020-11-25T01:00:58ZengSE "Dnipropetrovsk medical academy of Health Ministry of Ukraine"Medičnì Perspektivi2307-04042307-04042015-06-012025462Primary dyslipidemia and cardiometabolic risk: potential of pitavastatinBerezin A.E.0Sheychenko T.V.1Berezina T.A.2Vishnevaya N.V.3Kovalenko N.V.4Kulik Z.I.5Мoiseenko I.А.6State Medical University , Internal Medicine Department N 2City hospital N 7 Vita Center LTD SI «SМSD N 6, HM of Ukraine»SI «SМSD N 6, HM of Ukraine»SI «SМSD N 6, HM of Ukraine»SI «SМSD N 6, HM of Ukraine»The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in patients at high risk with concomitant metabolic comorbidities. Evidences for novel modern approaches regarding primary prevention of cardiovascular events among dyslipidemic patients are considered. The potential role of lipid-lowering treatment with statins and their role in reducing the cardiovascular risk are discussed. Information about modern methods of minimization of residual cardiovascular risk using a combined lipid-lowering strategies and new representatives of the statins are provided. It has been discussed various strategies of statin administering to patients with dyslipidemia of different age with exiting comorbidities, such as diabetes mellitus, obesity, metabolic syndrome. Objective findings and treatment approaches obtained from the patient with obesity, metabolic syndrome, and asymptomatic atherosclerosis are provided. The role of pitavastatin in primary prevention program of cardiovascular events is discussed.http://medpers.dsma.dp.ua/issues/2015/N2/54-62.pdfdyslipidemiacardiometabolic riskstatinspitavastatin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Berezin A.E. Sheychenko T.V. Berezina T.A. Vishnevaya N.V. Kovalenko N.V. Kulik Z.I. Мoiseenko I.А. |
spellingShingle |
Berezin A.E. Sheychenko T.V. Berezina T.A. Vishnevaya N.V. Kovalenko N.V. Kulik Z.I. Мoiseenko I.А. Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin Medičnì Perspektivi dyslipidemia cardiometabolic risk statins pitavastatin |
author_facet |
Berezin A.E. Sheychenko T.V. Berezina T.A. Vishnevaya N.V. Kovalenko N.V. Kulik Z.I. Мoiseenko I.А. |
author_sort |
Berezin A.E. |
title |
Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin |
title_short |
Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin |
title_full |
Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin |
title_fullStr |
Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin |
title_full_unstemmed |
Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin |
title_sort |
primary dyslipidemia and cardiometabolic risk: potential of pitavastatin |
publisher |
SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine" |
series |
Medičnì Perspektivi |
issn |
2307-0404 2307-0404 |
publishDate |
2015-06-01 |
description |
The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in patients at high risk with concomitant metabolic comorbidities. Evidences for novel modern approaches regarding primary prevention of cardiovascular events among dyslipidemic patients are considered. The potential role of lipid-lowering treatment with statins and their role in reducing the cardiovascular risk are discussed. Information about modern methods of minimization of residual cardiovascular risk using a combined lipid-lowering strategies and new representatives of the statins are provided. It has been discussed various strategies of statin administering to patients with dyslipidemia of different age with exiting comorbidities, such as diabetes mellitus, obesity, metabolic syndrome. Objective findings and treatment approaches obtained from the patient with obesity, metabolic syndrome, and asymptomatic atherosclerosis are provided. The role of pitavastatin in primary prevention program of cardiovascular events is discussed. |
topic |
dyslipidemia cardiometabolic risk statins pitavastatin |
url |
http://medpers.dsma.dp.ua/issues/2015/N2/54-62.pdf |
work_keys_str_mv |
AT berezinae primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT sheychenkotv primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT berezinata primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT vishnevayanv primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT kovalenkonv primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT kulikzi primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT moiseenkoia primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin |
_version_ |
1725211661513523200 |